Literature DB >> 8314782

Functional domains of the human B-myb gene product.

H Nakagoshi1, Y Takemoto, S Ishii.   

Abstract

Three members of the human myb gene family (c-myb, A-myb, and B-myb) encode transcriptional regulators that can bind to specific DNA sequences. High levels of c-myb expression are usually found in immature hemopoietic cells, but the B-myb is more commonly expressed in many types of cells. To understand the regulation of the activity of B-myb gene product (B-Myb), its functional domains were analyzed. Like c-Myb, B-Myb also has a transcriptional activation domain containing a cluster of acidic amino acids in the region downstream of the DNA-binding domain, which consists of three tandem repeats of 51-52 amino acids. In contrast to c-Myb, B-Myb does not contain a negative regulatory domain. Furthermore, the multiple nuclear localization signals are in at least two regions in the COOH-terminal half of B-Myb, and one of them is adjacent to a potential cdc2 kinase site. These results indicate that B-Myb contains DNA-binding and transcriptional activation domains similar to those of c-Myb, but a regulatory mechanism of B-Myb activity is quite different from that for c-Myb.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314782

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Phenotypic and morphological characterization of neuroblastoma cells constitutively expressing B-myb.

Authors:  S Scarpa; A Negroni; R Amendola; P Signorelli; B Calabretta; A Modesti; G Raschellà
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Activation of human B-MYB by cyclins.

Authors:  A Sala; M Kundu; I Casella; A Engelhard; B Calabretta; L Grasso; M G Paggi; A Giordano; R J Watson; K Khalili; C Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  The highly conserved DNA-binding domains of A-, B- and c-Myb differ with respect to DNA-binding, phosphorylation and redox properties.

Authors:  S Bergholtz; T O Andersen ; K B Andersson; J Borrebaek; B Lüscher; O S Gabrielsen
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

4.  The C-terminal domain of B-Myb acts as a positive regulator of transcription and modulates its biological functions.

Authors:  I H Oh; E P Reddy
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

5.  The Wnt-NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3.

Authors:  Toshihiro Kurahashi; Teruaki Nomura; Chie Kanei-Ishii; Yoichi Shinkai; Shunsuke Ishii
Journal:  Mol Biol Cell       Date:  2005-07-29       Impact factor: 4.138

6.  Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor.

Authors:  T Nomura; M M Khan; S C Kaul; H D Dong; R Wadhwa; C Colmenares; I Kohno; S Ishii
Journal:  Genes Dev       Date:  1999-02-15       Impact factor: 11.361

7.  The carboxyterminus of human c-myb protein stimulates activated transcription in trans.

Authors:  G Vorbrueggen; F Kalkbrenner; S Guehmann; K Moelling
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

8.  Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.

Authors:  D Lin; M Fiscella; P M O'Connor; J Jackman; M Chen; L L Luo; A Sala; S Travali; E Appella; W E Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  A B-Myb complex containing clathrin and filamin is required for mitotic spindle function.

Authors:  Tomohiro Yamauchi; Takefumi Ishidao; Teruaki Nomura; Toshie Shinagawa; Yasunori Tanaka; Shigenobu Yonemura; Shunsuke Ishii
Journal:  EMBO J       Date:  2008-06-12       Impact factor: 11.598

10.  Interaction of the transactivation domain of B-Myb with the TAZ2 domain of the coactivator p300: molecular features and properties of the complex.

Authors:  Ojore Oka; Lorna C Waters; Sarah L Strong; Nuvjeevan S Dosanjh; Vaclav Veverka; Frederick W Muskett; Philip S Renshaw; Karl-Heinz Klempnauer; Mark D Carr
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.